Drug intelligence / Profile preview

Z326E

Development stage: Unknown
Lead developer: Shandong Laboratory of Yantai Drug Discovery
Modality: Small Molecules

Overview

Z326E is a Class 1 small molecule new drug candidate developed by the Shandong Laboratory of Yantai Drug Discovery (also known as the Yantai Institute of Materia Medica). The drug has obtained clinical trial approval in China and is currently undergoing Phase II clinical trials. While the specific molecular target and therapeutic indication of Z326E have not been publicly disclosed, the developing institute focuses on major therapeutic areas including malignant tumors, cardiovascular and cerebrovascular diseases, and metabolic disorders.

Beyond the preview

Go deeper on Z326E.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Z326E.

Explore the full profile